Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials.
Saved in:
| Title: | Pregabalin in patients with post‐traumatic peripheral neuropathic pain: A meta‐analysis of randomized controlled trials. |
|---|---|
| Authors: | Maleki, Mohsen Saheban, Zamani, Zahra, Amiri, Roya, Kakhki, Samaneh, Jafari, Mojtaba, Amani, Behnam, Amani, Bahman, Amanat, Nasir |
| Source: | Pain Practice. Jul2023, Vol. 23 Issue 6, p595-602. 8p. 1 Diagram, 3 Charts, 1 Graph. |
| Subjects: | Peripheral nerve injuries, Pregabalin, Drug efficacy, Online information services, Medical databases, Meta-analysis, Confidence intervals, Neuralgia, Systematic reviews, Patients, Treatment effectiveness, Randomized controlled trials, Placebos, Emergency medical services, Descriptive statistics, MEDLINE, Data analysis software, Patient safety |
| Abstract: | Objective: The aim of the study was to investigate the safety and efficacy of pregabalin versus placebo in post‐traumatic peripheral neuropathic pain (PTNP). Methods: PubMed, Cochrane Library, Web of Science, and Google Scholar were searched for relevant evidence up to January 2022. The Cochran tool was used to assess the quality of randomized clinical trials (RCTs). Data analysis was performed using Comprehensive Meta‐Analysis software. Results: Three RCTs involving 821 patients were included in the meta‐analysis. A significant difference was observed between pregabalin and placebo in terms of the pain score (the standardized mean difference [SMD] = −0.14, 95% CI: 0.28 to −0.006, p = 0.04) and sleep interference (MD = −0.25, 95% CI: −0.39 to −0.11, p = 0.00). There was also a significant difference between pregabalin and placebo regarding somnolence (risk ratio [RR] = 2.78; 95% CI: 1.64–4.71, p = 0.00), dizziness (RR = 4.13; 95% CI: 2.71–6.28, p = 0.00), and disturbance in attention (RR: 2.97; 95% CI: 1.02–8.65, p = 0.04). However, no significant difference was observed between pregabalin and placebo in terms of headache (RR = 1.20; 95% CI: 0.70–2.06, p = 0.50), fatigue (RR = 1.42; 95% CI: 0.82–2.47, p = 0.20), nausea (RR = 1.52; 95% CI: 0.88–2.62, p = 0.13), constipation (RR = 1.84; 95% CI: 0.78–4.29, p = 0.15), and discontinuation (RR = 1.52; 95% CI: 0.45–5.06, p = 0.49). Conclusion: Compared with placebo, pregabalin showed better efficacy in reducing PTNP and improving sleep interference. However, it was associated with higher adverse events. Further RCTs are needed to confirm these findings. [ABSTRACT FROM AUTHOR] |
| Copyright of Pain Practice is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
